interferon-alpha2b
- Generic Name
- interferon-alpha2b
Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)
Phase 1
Completed
- Conditions
- Coronavirus Disease 2019
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2022-08-05
- Lead Sponsor
- Pontificia Universidad Catolica de Chile
- Target Recruit Count
- 173
- Registration Number
- NCT04988217
- Locations
- 🇨🇱
Red de Salud UC Christus, Santiago, RM, Chile
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol
Phase 2
Completed
- Conditions
- CoVid 19 Positive
- Interventions
- Drug: Convalescent Serum
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- The Camelot Foundation
- Target Recruit Count
- 1800
- Registration Number
- NCT04349410
- Locations
- 🇺🇸
FHHI-OI-Camelot; QME, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath